STOCK TITAN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Overview of Illumina Inc.

Illumina Inc. (NASDAQ: ILMN) is a global leader in DNA sequencing and array-based technologies, revolutionizing the field of genomics through innovative tools and solutions. The company’s core mission is to unlock the power of the genome to improve human health, enabling transformative advancements in personalized medicine, disease research, drug discovery, and agricultural innovation. By providing cutting-edge sequencing instruments, consumables, and bioinformatics solutions, Illumina empowers researchers, clinicians, and organizations across diverse sectors to decode genetic information with unprecedented precision and scale.

Core Business Areas

Illumina’s business model is centered around the development and commercialization of high-throughput sequencing systems, consumables, and services that cater to a wide range of applications. The company’s offerings include:

  • Sequencing Instruments: Illumina’s flagship platforms, such as the NovaSeq™ series, deliver scalable, high-throughput sequencing capabilities that support whole-genome sequencing, transcriptomics, and multiomics.
  • Consumables: Proprietary reagents, flow cells, and sample preparation kits designed for seamless integration with Illumina’s sequencing systems.
  • Bioinformatics Solutions: Advanced software tools like DRAGEN™ enable rapid, accurate analysis of genomic data, streamlining workflows from raw data to actionable insights.
  • Array-Based Technologies: Microarrays for targeted genetic screening, serving applications in consumer genomics, agriculture, and clinical diagnostics.

Industry Applications

Illumina’s technologies are widely adopted across various industries, including:

  • Life Sciences Research: Supporting basic and applied research in genomics, transcriptomics, and epigenetics.
  • Oncology: Enabling comprehensive genomic profiling, biomarker discovery, and precision oncology research.
  • Reproductive Health: Advancing non-invasive prenatal testing (NIPT) and carrier screening.
  • Agriculture: Facilitating crop improvement and livestock breeding through genomic insights.
  • Population Genomics: Partnering with national initiatives to sequence diverse populations and drive precision medicine.

Competitive Position and Innovation

Illumina maintains its leadership in the genomics space through continuous innovation and a customer-centric approach. Its proprietary technologies, such as XLEAP-SBS™ chemistry and DRAGEN bioinformatics, set new benchmarks for accuracy, speed, and scalability in sequencing. The company’s commitment to end-to-end solutions, including sample preparation, sequencing, and data analysis, ensures a seamless user experience and accelerates scientific discovery.

Market Significance

Illumina’s impact extends beyond technology; it plays a pivotal role in advancing global health initiatives. From supporting population genomics programs to enabling breakthroughs in cancer research and rare disease diagnostics, Illumina’s contributions are shaping the future of healthcare and biotechnology. Its collaborations with academic institutions, clinical labs, and industry leaders further solidify its position as a trusted partner in the genomics ecosystem.

Conclusion

With its unwavering focus on innovation, scalability, and customer needs, Illumina continues to lead the way in genomics, empowering researchers and clinicians to harness the full potential of genetic information. Its comprehensive portfolio of products and services positions it as an indispensable player in the pursuit of improved health outcomes and scientific advancement.

Rhea-AI Summary
Illumina (ILMN) conducted a study to uncover links between an endogenous retrovirus and cancer in koalas. The San Diego Zoo's koala population faces a significant challenge due to the koala retrovirus (KoRV), which is associated with fatal conditions such as susceptibility to bacterial infections, leukemia, lymphoma, and other cancers. The study aims to understand the genetic implications of this virus and its impact on koala health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary
Illumina Ventures Labs (IVL) is now operational and finalizing agreements with several startup companies. IVL is part of Illumina Ventures, supporting early-stage genomics startups. IVL provides fully equipped genomics labs, mentorship, and connections to other companies within the Illumina Ventures portfolio. Companies can stay in Labs for up to eighteen months and employ virtual and hybrid formats. After leaving the Labs, companies will be de-risked and attractive investment opportunities for the wider venture capital community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary
GRAIL, LLC (ticker symbol: GRL) and BeniComp partner to make Galleri® multi-cancer early detection (MCED) screening test available to eligible patients through BeniComp Select members. This partnership aims to enhance proactive and preventive health management, offering better access to care and equipping participants with proactive cancer screening tools. The Galleri® test, introduced in 2021, utilizes next-generation sequencing and machine learning to detect a signal shared by many cancers, including those without recommended screenings. The collaboration between GRAIL and BeniComp signifies a step forward in early cancer detection and preventive health measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
Rhea-AI Summary
Illumina, Inc. (Nasdaq: ILMN) announces unaudited preliminary financial results for Q4 2023 and fiscal year 2023, with consolidated revenue of approximately $1,115 million for Q4 2023, up 3% from Q4 2022, and approximately $4,497 million for fiscal year 2023, down 2% from fiscal year 2022. Core Illumina revenue was approximately $1,090 million for Q4 2023, up 2% from Q4 2022, and approximately $4,431 million for fiscal year 2023, down 3% from fiscal year 2022. The company also shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) signs collaboration agreement with Janssen Research & Development, LLC for the development of a novel molecular residual disease assay using whole-genome sequencing for oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
Rhea-AI Summary
Illumina, Inc. (ILMN) to Release Q4 and Full Year 2023 Results on February 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) delivered approximately 86,000 whole genomes in 2023, including a unique diverse ancestry cohort. The company announced three new members of the Alliance for Genomic Discovery (AGD), including Bristol Myers Squibb (BMS), GSK, and Novo Nordisk, who will co-fund the whole-genome sequencing of 250,000 DNA samples. This collaboration aims to generate and analyze more genomic, multimodal phenotypic, and multiomic data to improve human health and drug discovery. AGD completed whole-genome sequencing of approximately 86,000 DNA samples, including a diverse ancestry cohort of 35,000 individuals primarily of African ancestry. The alliance is applying innovative, large-scale analysis tools to the DNA data to identify disease associations and drug targets for intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) reiterates its view that there is a viable alternative to the proposed merger between SomaLogic, Inc. (SLGC) and Standard BioTools Inc. (LAB). They believe that SomaLogic's cash position and near-term commercial opportunities mitigate the need for the merger, and they urge shareholders to vote against it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Nucleus Genomics (NUCL) is partnering with Illumina to scale their vision of leveraging whole-genome sequencing (WGS) to build a more proactive health care system. The company aims to make WGS widely available to the public and is set to launch in the US in 2024. Nucleus has received $18 million in funding and is focused on combining over 70,000 genetic tests into one comprehensive product, including polygenic risk scores (PRS) and nongenetic information for a more complete risk assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) executives to speak at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Webcast and Q&A session to be available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences

FAQ

What is the current stock price of Illumina (ILMN)?

The current stock price of Illumina (ILMN) is $84.2 as of March 3, 2025.

What is the market cap of Illumina (ILMN)?

The market cap of Illumina (ILMN) is approximately 13.9B.

What does Illumina Inc. specialize in?

Illumina specializes in DNA sequencing and array-based technologies, providing tools and services for genetic analysis across research, clinical, and applied markets.

How does Illumina generate revenue?

Illumina generates revenue through the sale of sequencing instruments, consumables, and bioinformatics solutions, as well as providing related services.

What industries use Illumina’s technologies?

Illumina’s technologies are used in life sciences research, oncology, reproductive health, agriculture, and population genomics, among other fields.

What makes Illumina’s technology unique?

Illumina’s proprietary technologies, such as XLEAP-SBS chemistry and DRAGEN bioinformatics, offer unmatched accuracy, scalability, and efficiency in genomic sequencing and analysis.

How does Illumina support population genomics programs?

Illumina collaborates with national initiatives to sequence diverse populations, providing the tools and expertise needed to advance precision medicine and public health.

What are the key applications of Illumina’s sequencing platforms?

Key applications include whole-genome sequencing, transcriptomics, multiomics, biomarker discovery, and targeted genetic screening.

What role does Illumina play in precision medicine?

Illumina’s technologies enable the identification of genetic biomarkers and actionable mutations, supporting personalized treatment strategies in precision medicine.

What is Illumina’s approach to innovation?

Illumina focuses on developing end-to-end solutions that integrate sample preparation, sequencing, and data analysis, ensuring seamless workflows and accelerating discovery.
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

13.91B
157.59M
0.27%
107.22%
3.76%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO